The aim of this study was to evaluate the function of the AbioCor artificial heart implanted in calves that underwent treadmill exercise testing and to investigate the cardiovascular and metabolic responses during exercise. Six calves were implanted with the AbioCor. One week after surgery, exercise training was undertaken and animals were put on a treadmill at a speed of 0.5-1.0 mph, with the AbioCor operating at the maximum heart rate of 150 beats per minute. During exercise, the left and right atrial pressures were significantly increased (p < 0.05). Oxygen consumption was significantly elevated (p < 0.05). Lactate levels did not significantly increase (p > 0.05). The index of metabolic adequacy remained higher than 2.0, indicating that there was no substantial transition to anaerobic metabolism during exercise. There was an increased extraction of oxygen during exercise to meet the increased energy demands. Our study demonstrated that animals implanted with the AbioCor heart were able to maintain aerobic metabolism during low levels of exercise testing.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.mat.0000084106.25889.fe | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
2001: An artificial heart odyssey.
Artif Organs
July 2023
Division of Cardiothoracic Surgery, Department of Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
The quest to replace the natural heart with an artificial one as a permanent system is among the remaining holy grails in medicine and surgery. Beginning in 1969, when the first total artificial heart (TAH) was implanted into a human, to the present, several types have been developed-the AbioCor was among them. On November 5th, 2001, our team at Hahnemann University Hospital in Philadelphia, Pennsylvania placed the world's fifth AbioCor.
View Article and Find Full Text PDFThe evolving role of the total artificial heart in the management of end-stage congenital heart disease and adolescents.
ASAIO J
May 2015
From The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Advances in medical therapies have yielded improvement in morbidity and a decrease in mortality for patients with congenital heart disease, both surgically palliated and uncorrected. An unintended consequence is a cohort of adolescent and adult patients with heart failure who require alternative therapies. One intriguing option is placement of a total artificial heart (TAH) either as a bridge to transplant or as a destination therapy.
View Article and Find Full Text PDFThe total artificial heart.
Panminerva Med
September 2011
Division of Thoracic and Cardiovascular Surgery, University of Louisville, Louisville, KY, USA.
In the 1960s, cardiac surgeons and biomedical engineers pioneered the development of total artificial hearts (TAH) for the treatment of left and right heart failure. As we mark the 10th anniversary of the first implantation of the AbioCor device, the use of TAH has been limited, having failed to reach its envisioned potential and promise as an alternative therapy to heart transplantation. The Syncardia/CardioWest device, originally developed 30 years ago as the Jarvik TAH and later renamed the CardioWest TAH, continues to be used clinically in over 50 centers within the US and Europe having supported over 900 patients worldwide.
View Article and Find Full Text PDFCatheterization of the AbioCor implantable replacement heart: evaluation of the unique physiology created by the device.
Tex Heart Inst J
November 2006
The Department of Cardiopulmonary Transplantation and Assist Devices, Texas Heart Institute at St. Luke's Episcopal Hospital, Houston, Texas 77030, USA.
We performed the 1st catheterization of an AbioCor implantable replacement heart, in a patient who had developed high right-sided pump pressures, to determine whether the high pressures were caused by graft kinking or obstruction.
View Article and Find Full Text PDFSurgically implanted devices: ethical challenges in a very different kind of research.
Thorac Surg Clin
November 2005
College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Research on surgically implanted devices not only can raise issues familiar from drug studies, but also can raise special challenges. This article suggests some ways in which device trials can raise distinctive ethical issues. The AbioCor artificial heart trial is used as an example.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!